These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Golabi P; Bush H; Younossi ZM Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260 [TBL] [Abstract][Full Text] [Related]
3. Treatment of non-alcoholic fatty liver disease. Dyson J; Day C Dig Dis; 2014; 32(5):597-604. PubMed ID: 25034293 [TBL] [Abstract][Full Text] [Related]
4. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Rotman Y; Sanyal AJ Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933 [TBL] [Abstract][Full Text] [Related]
5. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. Makri E; Cholongitas E; Tziomalos K World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393 [TBL] [Abstract][Full Text] [Related]
6. [Treatment Options in Non-alcoholic Fatty Liver Disease]. Kim W Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104 [TBL] [Abstract][Full Text] [Related]
7. Current management of non-alcoholic fatty liver disease. Lisboa QC; Costa SM; Couto CA Rev Assoc Med Bras (1992); 2016 Dec; 62(9):872-878. PubMed ID: 28001263 [TBL] [Abstract][Full Text] [Related]
8. The diagnosis and treatment of non-alcoholic fatty liver disease. Altinbas A; Sowa JP; Hasenberg T; Canbay A Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905 [TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Adorini L; Pruzanski M; Shapiro D Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341 [TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Oh H; Jun DW; Saeed WK; Nguyen MH Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
12. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998 [TBL] [Abstract][Full Text] [Related]